Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial Nov 3, 2022
Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization Nov 2, 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Oct 31, 2022
Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A Oct 27, 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B Oct 25, 2022
Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones Sep 21, 2022
Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Sep 8, 2022
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR Apr 25, 2022
